Hepatocellular Carcinoma Presenting with Pseudoprogression in a Patient Receiving Atezolizumab Plus Bevacizumab Combination Therapy.
1/5 보강
A 65-year-old man with hepatocellular carcinoma and lung metastasis was treated with a combination of atezolizumab and bevacizumab.
APA
Osuga T, Kubo T, et al. (2025). Hepatocellular Carcinoma Presenting with Pseudoprogression in a Patient Receiving Atezolizumab Plus Bevacizumab Combination Therapy.. Internal medicine (Tokyo, Japan), 64(14), 2148-2154. https://doi.org/10.2169/internalmedicine.4710-24
MLA
Osuga T, et al.. "Hepatocellular Carcinoma Presenting with Pseudoprogression in a Patient Receiving Atezolizumab Plus Bevacizumab Combination Therapy.." Internal medicine (Tokyo, Japan), vol. 64, no. 14, 2025, pp. 2148-2154.
PMID
39756877 ↗
Abstract 한글 요약
A 65-year-old man with hepatocellular carcinoma and lung metastasis was treated with a combination of atezolizumab and bevacizumab. Subsequently, the patient developed fever and new liver lesions, which were considered to indicate a pseudoprogression. Despite this, the treatment was continued. Three months later, computed tomography scans demonstrated that the new lesions had disappeared and both the primary tumor and metastases had shrunk. A partial response was achieved and maintained for two years. A histological examination revealed a predominance of CD8-positive lymphocytes and programmed death-ligand 1-positive tumor-associated macrophages, which may predict a positive response to this therapy. Pseudoprogression may therefore be a favorable prognostic factor in hepatocellular carcinoma.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Liver Neoplasms
- Male
- Carcinoma
- Hepatocellular
- Aged
- Antibodies
- Monoclonal
- Humanized
- Bevacizumab
- Antineoplastic Combined Chemotherapy Protocols
- Disease Progression
- Lung Neoplasms
- Treatment Outcome
- atezolizumab plus bevacizumab combination therapy
- hepatocellular carcinoma
- pseudoprogression
- tumor-associated macrophages
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.